The UC Davis/NIH NeuroMab Facility is a purely academic monoclonal antibody (mAb) facility as funded by NIH awards U24 NS050606 (2005-2014), R24 NS092991 (2015-2019), and U24 NS109113 (2019-present). Our mission is to provide a unique neuroscience-based approach to generating mouse mAbs optimized for use in mammalian brain (NeuroMabs), and to convert them into recombinant form. NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.  Our current efforts, as funded by NIH award U24 NS109113 (2019-2024) is to determine the sequence of these mAbs and convert them into recombinant form. This yields antibodies with enhanced value as being molecular defined reagents, and with the potential to expand their utility with recombinant engineering.  All of our conventional and recombinant antibodies, and the hybridoma cells and plasmids, respectively, that produce them are available through open access non-profit routes. 

The UC Davis/NIH NeuroMab Facility continues to serve as a resource to the entire neuroscience community through its generation of a collection of highly validated open access mAbs that serve as critical links between information from genomic and transcriptomic efforts and spatial proteomic approaches to brain function. Moreover, the unique neuroscience-based approach that the UC Davis/NIH NeuroMab Facility uses in its development and screening efforts yields reliable mAbs that might not otherwise be available, and the comprehensive biochemical and immunohistochemical verification will save countless investigators the time, money and effort of attempting to use expensive yet suboptimal reagents in their research.

James S. Trimmer, PhD. Founding Director

Karl D. Murray, PhD. Associate Director

UC Davis makes no warranties, either expressed or implied, concerning the accuracy, completeness, reliability, or suitability of the information contained on these Web pages or of the security or privacy of any information collected by these Web pages. All views expressed in the Web site are those of the author and not UC Davis.